Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | STAT1 | P42224 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456725 | 0.91 | ALDH1A1 (0.83) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL7556866 | 0.88 | ALDH1A1 (0.79) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL23455508 | 0.85 | RAB9A (1.00) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6816600 | 0.84 | GAA (0.74) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL28879978 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL14360821 | 0.83 | ALDH1A1 (0.70) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4371367 | 0.82 | KMT2A (0.74) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL5457306 | 0.82 | HPGD (0.74) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL1884508 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4053434 | 0.80 | ALDH1A1 (0.71) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022721-B1 | Method and composition for rejuvenating cells, tissues, organs, hair and nails | ULRICH PETER C | 2006-04-04 | — | — | US | disclosed |
| EP-1368029-A4 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | ULRICH PETER C | 2005-11-03 | — | — | US | disclosed |
| US-6777557-B2 | Method and composition for rejuvenating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2004-08-17 | — | — | US | disclosed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| EP-1368029-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | Farrington Pharmaceuticals, LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-12 | — | — | US | disclosed |
| WO-2002062301-A2 | METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188015-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | ALDH1A1 3396/4885NPC1 3338/4885RAB9A 1317/4885 |
| US-20050245512-A1 | Method and composition for rejuvinating cells, tissues organs, hair and nails | TERT, TELO2, HKDC1 | ALDH1A1 3396/4885NPC1 3338/4885RAB9A 1317/4885 |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | TYR, CRYZ, RHOT2 | ALDH1A1 3325/4885NPC1 405/4885RAB9A 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.